Genus Capital Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
Other funds holding UTHR
Genus Capital Management's UTHR Position: Q3 2026 in Review
Genus Capital Management reduced its United Therapeutics (UTHR) stake by 68% in Q3 2026, selling an estimated $3.53M and leaving 3,280 shares worth $1.78M. The position accounts for 0.18% of the portfolio, ranked #138.
Genus Capital Management first reported a position in UTHR in Q4 2025 and has held it in 4 quarters since. The position peaked at $5.48M in Q2 2026. 838 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.
- Genus Capital Management held 3,280 shares of United Therapeutics worth $1.78M as of Q3 2026.
- Genus Capital Management sold 6,835 United Therapeutics shares in Q3 2026, an estimated $3.53M.
- United Therapeutics made up 0.18% of Genus Capital Management's portfolio in Q3 2026, its #138 holding.
- Genus Capital Management first reported a position in United Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Genus Capital Management's United Therapeutics position peaked at $5.48M in Q2 2026.
- 838 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.
Based on Genus Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.